“You may choose to look the other way, but you can never say again that you did not know.”
— William Wilberforce
Pfizer and BioNTech will have to answer in court to legal claims by Moderna that they copied its innovative messenger RNA (mRNA) technology in the making of their COVID-19 biologic, Comirnaty. The patent infringement lawsuit filed in U.S. District Court for the District of Massachusetts and the Regional Court of Dusseldorf in Germany alleges that […]
As the debate continues surrounding the issue of bodily autonomy being violated by school and workplace COVID-19 vaccine mandates, a new research study that analyzed more than one million people has found that natural immunity to SARS-CoV-2 offers longer lasting protection than vaccination.1 The study, which was published in The New England Journal of Medicine […]
Techniker Krankenkasse, Germany’s largest health insurance company, reported that 437,593 of 11 million (1 in 25) insured individuals in 2021 had to undergo medical treatment as a result of adverse reactions from COVID-19 shots.1 COVID shots currently approved for use in Germany include Novavax’s Nuvaxovid, Moderna’s Spikevax, Pfizer/BioNTech’s Comirnaty, Johnson & Johnson/Janssen’s Ad26.COV2.S, AstraZeneca/Oxford University’s […]
Concerns about the adverse effects of mRNA COVID-19 shots continue to grow a year and a half after they began to be distributed under an Emergency Use Authorization (EUA) granted to Pfizer/BioNTech and Moderna by the U.S. Food and Drug Administration (FDA). Cases of herpes zoster (HZ) following messenger RNA (mRNA) COVID shots have been […]
On July 25, 2022, a committee of Japan’s Ministry of Health, Labor and Welfare announced that it would provide a lump-sum death benefit of ¥44.2 million ($324,000), plus an additional ¥212,000 for funeral expenses, to the family of an elderly woman who died shortly after receiving a COVID-19 shot. The committee determined there was a […]
Opinion | On July 13, 2022, the U.S. Food and Drug Administration (FDA) granted Emergency Use Authorization (EUA) to Novavax to distribute its experimental two-dose NVX-CoV2373 (also known as “Nuvaxovid” and “Covovax”) COVID-19 vaccine for use by adults. The decision was expected, given the favorable recommendation by the FDA’s Vaccines and Related Biological Products Advisory […]
In a new study published in the journal Andrology, researchers found what they believe to be a temporary decline of sperm concentration and total motile count among sperm donors in Israel three months following vaccination with Pfizer/BioNTech’s BNT162b2 (also known as “Comirnaty”) messenger RNA (mRNA) COVID-19 biologic.1 Study Investigates the Effect of the Pfizer COVID […]
Opinion | The Countermeasures Injury Compensation Program (CICP) is a program of the U.S. government that provide financial compensation for people who have suffered serious injuries or death from vaccines, biologics, antivirals or other drugs, as well medical devices used to “diagnose, prevent or treat a declared pandemic, epidemic or security threat.” The program was […]
Despite concerns about the risk of developing myocarditis (inflammation of the heart muscle) and pericarditis (inflammation of the lining of the heart) following vaccination with Novavax’s experimental NVX-CoV2373 (also known as “Nuvaxovid” and “Covovax”) COVID-19 vaccine, the U.S. Food and Drug Administration’s (FDA) Vaccines and Related Biological Products Advisory Committee (VRBPAC) voted on June 6, […]
A study by the University College London showed that serious Guillain-Barré syndrome (GBS), which can result in temporary or permanent paralysis, is a “small but significant” risk associated with AstraZeneca/Oxford University’s AZD1222 (or “Vaxzevria”) vaccine. Of the 996 cases of GBS that were recorded in the United Kingdoms’ National Immunisation Management System database between January […]